Copyright Reports & Markets. All rights reserved.

Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Insights and Forecast to 2026

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Introduction
  • 1.2 Key Market Segments in This Study
  • 1.3 Key Manufacturers Covered: Ranking of Global Top NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturers by Revenue in 2019
  • 1.4 Market by Type
    • 1.4.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Growth Rate by Type
    • 1.4.2 Serum biomarkers
    • 1.4.3 Hepatic fibrosis biomarkers
    • 1.4.4 Apoptosis biomarkers
    • 1.4.5 Oxidative stress biomarkers
    • 1.4.6 Others
  • 1.5 Market by Application
    • 1.5.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Growth Rate by Application
    • 1.5.2 Pharma & CRO Industry
    • 1.5.3 Hospitals
    • 1.5.4 Diagnostic Labs
    • 1.5.5 Academic Research Institutes
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Executive Summary

  • 2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, Estimates and Forecasts
    • 2.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Estimates and Forecasts 2015-2026
    • 2.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Capacity Estimates and Forecasts 2015-2026
    • 2.1.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Estimates and Forecasts 2015-2026
  • 2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers, Market Size by Producing Regions: 2015 VS 2020 VS 2026
  • 2.3 Analysis of Competitive Landscape
    • 2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 2.3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 2.3.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturers Geographical Distribution
  • 2.4 Key Trends for NASH (Non-alcoholic Steatohepatitis) Biomarkers Markets & Products
  • 2.5 Primary Interviews with Key NASH (Non-alcoholic Steatohepatitis) Biomarkers Players (Opinion Leaders)

3 Market Size by Manufacturers

  • 3.1 Global Top NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturers by Production Capacity
    • 3.1.1 Global Top NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturers by Production Capacity (2015-2020)
    • 3.1.2 Global Top NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturers by Production (2015-2020)
    • 3.1.3 Global Top NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturers Market Share by Production
  • 3.2 Global Top NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturers by Revenue
    • 3.2.1 Global Top NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturers by Revenue (2015-2020)
    • 3.2.2 Global Top NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturers Market Share by Revenue (2015-2020)
    • 3.2.3 Global Top 10 and Top 5 Companies by NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue in 2019
  • 3.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Manufacturers
  • 3.4 Mergers & Acquisitions, Expansion Plans

4 NASH (Non-alcoholic Steatohepatitis) Biomarkers Production by Regions

  • 4.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Historic Market Facts & Figures by Regions
    • 4.1.1 Global Top NASH (Non-alcoholic Steatohepatitis) Biomarkers Regions by Production (2015-2020)
    • 4.1.2 Global Top NASH (Non-alcoholic Steatohepatitis) Biomarkers Regions by Revenue (2015-2020)
  • 4.2 North America
    • 4.2.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Production (2015-2020)
    • 4.2.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2015-2020)
    • 4.2.3 Key Players in North America
    • 4.2.4 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Import & Export (2015-2020)
  • 4.3 Europe
    • 4.3.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Production (2015-2020)
    • 4.3.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2015-2020)
    • 4.3.3 Key Players in Europe
    • 4.3.4 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Import & Export (2015-2020)
  • 4.4 China
    • 4.4.1 China NASH (Non-alcoholic Steatohepatitis) Biomarkers Production (2015-2020)
    • 4.4.2 China NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2015-2020)
    • 4.4.3 Key Players in China
    • 4.4.4 China NASH (Non-alcoholic Steatohepatitis) Biomarkers Import & Export (2015-2020)
  • 4.5 Japan
    • 4.5.1 Japan NASH (Non-alcoholic Steatohepatitis) Biomarkers Production (2015-2020)
    • 4.5.2 Japan NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2015-2020)
    • 4.5.3 Key Players in Japan
    • 4.5.4 Japan NASH (Non-alcoholic Steatohepatitis) Biomarkers Import & Export (2015-2020)

5 NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption by Region

  • 5.1 Global Top NASH (Non-alcoholic Steatohepatitis) Biomarkers Regions by Consumption
    • 5.1.1 Global Top NASH (Non-alcoholic Steatohepatitis) Biomarkers Regions by Consumption (2015-2020)
    • 5.1.2 Global Top NASH (Non-alcoholic Steatohepatitis) Biomarkers Regions Market Share by Consumption (2015-2020)
  • 5.2 North America
    • 5.2.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption by Application
    • 5.2.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption by Countries
    • 5.2.3 U.S.
    • 5.2.4 Canada
  • 5.3 Europe
    • 5.3.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption by Application
    • 5.3.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption by Countries
    • 5.3.3 Germany
    • 5.3.4 France
    • 5.3.5 U.K.
    • 5.3.6 Italy
    • 5.3.7 Russia
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption by Application
    • 5.4.2 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption by Regions
    • 5.4.3 China
    • 5.4.4 Japan
    • 5.4.5 South Korea
    • 5.4.6 India
    • 5.4.7 Australia
    • 5.4.8 Taiwan
    • 5.4.9 Indonesia
    • 5.4.10 Thailand
    • 5.4.11 Malaysia
    • 5.4.12 Philippines
    • 5.4.13 Vietnam
  • 5.5 Central & South America
    • 5.5.1 Central & South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption by Application
    • 5.5.2 Central & South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption by Country
    • 5.5.3 Mexico
    • 5.5.3 Brazil
    • 5.5.3 Argentina
  • 5.6 Middle East and Africa
    • 5.6.1 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption by Application
    • 5.6.2 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption by Countries
    • 5.6.3 Turkey
    • 5.6.4 Saudi Arabia
    • 5.6.5 U.A.E

6 Market Size by Type (2015-2026)

  • 6.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Type (2015-2020)
    • 6.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Production by Type (2015-2020)
    • 6.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2015-2020)
    • 6.1.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Type (2015-2020)
  • 6.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Forecast by Type (2021-2026)
    • 6.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Forecast by Type (2021-2026)
    • 6.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Type (2021-2026)
    • 6.2.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price Forecast by Type (2021-2026)
  • 6.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

7 Market Size by Application (2015-2026)

  • 7.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Historic Breakdown by Application (2015-2020)
  • 7.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast by Application (2021-2026)

8 Corporate Profiles

  • 8.1 GENFIT SA
    • 8.1.1 GENFIT SA Corporation Information
    • 8.1.2 GENFIT SA Overview
    • 8.1.3 GENFIT SA Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
    • 8.1.4 GENFIT SA Product Description
    • 8.1.5 GENFIT SA Related Developments
  • 8.2 Gilead Sciences, Inc. (GILD)
    • 8.2.1 Gilead Sciences, Inc. (GILD) Corporation Information
    • 8.2.2 Gilead Sciences, Inc. (GILD) Overview
    • 8.2.3 Gilead Sciences, Inc. (GILD) Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
    • 8.2.4 Gilead Sciences, Inc. (GILD) Product Description
    • 8.2.5 Gilead Sciences, Inc. (GILD) Related Developments
  • 8.3 AstraZeneca
    • 8.3.1 AstraZeneca Corporation Information
    • 8.3.2 AstraZeneca Overview
    • 8.3.3 AstraZeneca Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
    • 8.3.4 AstraZeneca Product Description
    • 8.3.5 AstraZeneca Related Developments
  • 8.4 Novartis AG
    • 8.4.1 Novartis AG Corporation Information
    • 8.4.2 Novartis AG Overview
    • 8.4.3 Novartis AG Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
    • 8.4.4 Novartis AG Product Description
    • 8.4.5 Novartis AG Related Developments
  • 8.5 Bristol-Myers Squibb Company
    • 8.5.1 Bristol-Myers Squibb Company Corporation Information
    • 8.5.2 Bristol-Myers Squibb Company Overview
    • 8.5.3 Bristol-Myers Squibb Company Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
    • 8.5.4 Bristol-Myers Squibb Company Product Description
    • 8.5.5 Bristol-Myers Squibb Company Related Developments
  • 8.6 Allergan Plc
    • 8.6.1 Allergan Plc Corporation Information
    • 8.6.2 Allergan Plc Overview
    • 8.6.3 Allergan Plc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
    • 8.6.4 Allergan Plc Product Description
    • 8.6.5 Allergan Plc Related Developments
  • 8.7 Novo Nordisk A/S
    • 8.7.1 Novo Nordisk A/S Corporation Information
    • 8.7.2 Novo Nordisk A/S Overview
    • 8.7.3 Novo Nordisk A/S Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
    • 8.7.4 Novo Nordisk A/S Product Description
    • 8.7.5 Novo Nordisk A/S Related Developments
  • 8.8 Boehringer Ingelheim
    • 8.8.1 Boehringer Ingelheim Corporation Information
    • 8.8.2 Boehringer Ingelheim Overview
    • 8.8.3 Boehringer Ingelheim Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
    • 8.8.4 Boehringer Ingelheim Product Description
    • 8.8.5 Boehringer Ingelheim Related Developments
  • 8.9 Pfizer Inc
    • 8.9.1 Pfizer Inc Corporation Information
    • 8.9.2 Pfizer Inc Overview
    • 8.9.3 Pfizer Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
    • 8.9.4 Pfizer Inc Product Description
    • 8.9.5 Pfizer Inc Related Developments

9 NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Forecast by Regions

  • 9.1 Global Top NASH (Non-alcoholic Steatohepatitis) Biomarkers Regions Forecast by Revenue (2021-2026)
  • 9.2 Global Top NASH (Non-alcoholic Steatohepatitis) Biomarkers Regions Forecast by Production (2021-2026)
  • 9.3 Key NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Regions Forecast
    • 9.3.1 North America
    • 9.3.2 Europe
    • 9.3.3 China
    • 9.3.4 Japan

10 NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast by Region

  • 10.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast by Region (2021-2026)
  • 10.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast by Region (2021-2026)
  • 10.3 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast by Region (2021-2026)
  • 10.4 Asia Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast by Region (2021-2026)
  • 10.5 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast by Region (2021-2026)
  • 10.6 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumption Forecast by Region (2021-2026)

11 Value Chain and Sales Channels Analysis

  • 11.1 Value Chain Analysis
  • 11.2 Sales Channels Analysis
    • 11.2.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Channels
    • 11.2.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Distributors
  • 11.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Customers

12 Market Opportunities & Challenges, Risks and Influences Factors Analysis

  • 12.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry
  • 12.2 Market Trends
  • 12.3 Market Opportunities and Drivers
  • 12.4 Market Challenges
  • 12.5 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Risks/Restraints
  • 12.6 Porter's Five Forces Analysis

13 Key Finding in The Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Study

    14 Appendix

    • 14.1 Research Methodology
      • 14.1.1 Methodology/Research Approach
      • 14.1.2 Data Source
    • 14.2 Author Details

    NASH (Non-alcoholic Steatohepatitis) Biomarkers market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global NASH (Non-alcoholic Steatohepatitis) Biomarkers market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.

    Segment by Type, the NASH (Non-alcoholic Steatohepatitis) Biomarkers market is segmented into
    Serum biomarkers
    Hepatic fibrosis biomarkers
    Apoptosis biomarkers
    Oxidative stress biomarkers
    Others

    Segment by Application, the NASH (Non-alcoholic Steatohepatitis) Biomarkers market is segmented into
    Pharma & CRO Industry
    Hospitals
    Diagnostic Labs
    Academic Research Institutes

    Regional and Country-level Analysis
    The NASH (Non-alcoholic Steatohepatitis) Biomarkers market is analysed and market size information is provided by regions (countries).
    The key regions covered in the NASH (Non-alcoholic Steatohepatitis) Biomarkers market report are North America, Europe, China and Japan. It also covers key regions (countries), viz, the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of production capacity, price and revenue for the period 2015-2026.
    Competitive Landscape and NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share Analysis

    NASH (Non-alcoholic Steatohepatitis) Biomarkers market competitive landscape provides details and data information by manufacturers. The report offers comprehensive analysis and accurate statistics on production capacity, price, revenue of NASH (Non-alcoholic Steatohepatitis) Biomarkers by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on production, revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue, and the production capacity, price, revenue generated in NASH (Non-alcoholic Steatohepatitis) Biomarkers business, the date to enter into the NASH (Non-alcoholic Steatohepatitis) Biomarkers market, NASH (Non-alcoholic Steatohepatitis) Biomarkers product introduction, recent developments, etc.
    The major vendors covered:
    GENFIT SA
    Gilead Sciences, Inc. (GILD)
    AstraZeneca
    Novartis AG
    Bristol-Myers Squibb Company
    Allergan Plc
    Novo Nordisk A/S
    Boehringer Ingelheim
    Pfizer Inc

    Buy now